Anne Westermann

Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial

Michael Hallek, Kirsten Fischer, Guenter Fingerle-Rowson et al. · The Lancet · 2010 · 1.9K citations

Medicine, Oncology, Pharmacotherapy +10

First-line therapy with fludarabine compared with chlorambucil does not result in a major benefit for elderly patients with advanced chronic lymphocytic leukemia

Barbara Eichhorst, Raymonde Busch, Stephan Stilgenbauer et al. · Blood · 2009 · 333 citations

Medicine, Oncology, Pharmacotherapy +7

Immunochemotherapy with Fludarabine (F), Cyclophosphamide (C), and Rituximab (R) (FCR) Versus Fludarabine and Cyclophosphamide (FC) Improves Response Rates and Progression-Free Survival (PFS) of Previously Untreated Patients (pts) with Advanced Chronic Lymphocytic Leukemia (CLL)

Michael Hallek, Guenter Fingerle-Rowson, Anna Maria Fink et al. · Blood · 2008 · 134 citations

Medicine, Oncology, Pharmacotherapy +14

First-Line Treatment with Fludarabine (F), Cyclophosphamide (C), and Rituximab (R) (FCR) Improves Overall Survival (OS) in Previously Untreated Patients (pts) with Advanced Chronic Lymphocytic Leukemia (CLL): Results of a Randomized Phase III Trial On Behalf of An International Group of Investigators and the German CLL Study Group.

Michael Hallek, Guenter Fingerle-Rowson, Anna‐Maria Fink et al. · Blood · 2009 · 90 citations

Medicine, Oncology, Pharmacotherapy +12

Sequential chemoimmunotherapy of fludarabine, mitoxantrone, and cyclophosphamide induction followed by alemtuzumab consolidation is effective in T‐cell prolymphocytic leukemia

Georg Hopfinger, Raymonde Busch, Natali Pflug et al. · Cancer · 2013 · 72 citations

Medicine, Oncology, Pharmacology +17